This site is for health professionals and their patients. Customers will require a fulfillment code to access our virtual dispensary.
雖然草莓和蔓越莓等漿果通常被稱為“超級食品”並具有許多健康益處,但已證明全食物中生物活性多酚的生物利用度相對較差。[3][4] 然而,在目前的研究中, 在研究參與者的血液中可以鑑定和檢測到四個活性多酚化合物的濃度和GlucoPhenol的代謝物或許是從中觀察到的益處。 研究中使用的 GlucoPhenol 由來自北美農場的蔓越莓和奧爾良草莓提取物的專有混合物組成,由研究合作夥伴專門開發。 這種特定的多酚混合物現在僅在 Atrium Innovations 旗下的三個品牌 Pure Encapsulations、Douglas Laboratories 和 Genestra 中提供。
這項研究是 INAF 和 Atrium Innovations 多年合作研究的一部分,旨在探索生活方式和營養干預對心臟代謝健康的影響。 除了多酚,研究人員還探索了魚油和全身酶的臨床應用及其在改善心臟代謝健康結果方面的作用。
該研究包括 41 名年齡介乎 40 至 70 歲之間的健康但對胰島素有抵抗的參與者,每個參與者的體重指數 (BMI) ≥ 25 kg/m2,在一項平行、雙盲、對照和隨機的 6 週臨床試驗中進行。 在整個研究期間,禁止食用漿果、葡萄酒、多酚補充劑和所有含有漿果或葡萄酒的產品。 通過高胰島素-正常血糖鉗評估胰島素敏感性,並在實驗開始和結束時進行2小時口服葡萄糖耐量試驗。 結果表明,GlucoPhenol 使胰島素敏感性 (M/I) 增加了 14% (+0·9 ± 0·5 x103 mg·kg-1·min-1·pmol-1),而對照組降低了胰島素敏感性 (M/I) 7% (-0·5 ± 0·5 x103 mg·kg-1·min-1·pmol-1),組間差異結果為 21%。 胰島素敏感性的改善在統計學上(P = 0·03)和臨床上都是顯著的。
Atrium Innovations 提供了本研究中使用的 GlucoPhenol 和對照產品。 該研究得到了魁北克生物過程研究與創新聯盟 (CRIBIQ)、Atrium Innovations Inc. 和 Nutra Canada Inc.(現為 Diana Food Inc. 的成員)的支持。
有關更多信息,請在此處查看完整的研究。
INAF 一個由著名的多學科科學家組成的公認網絡,共同努力推進有關人類營養及其對健康影響的知識。 在過去十年中,INAF 組建了最大的加拿大研究人員團隊(80 歲以上),致力於了解食物、食物成分、營養和健康之間的複雜關係,以及它們在預防慢性病中所起的作用。 INAF 將科學用於營養服務,以履行其使命,並確保其行動產生有利於人口健康和生物食品部門的具體而持久的結果。
Atrium Innovations Inc. 是以創新和科學為基礎的天然健康產品,在發展、製造和商業化中得到全球的認同的領導者,產品分佈在全球超過 35 個國家。 公司擁有以科學, 創新和教育為主的醫療從業者和專業零售產品品牌。 Atrium 擁有 1,300 多名員工,並運營著七家製造工廠,所有工廠均符合現行良好生產規範。 Atrium Innovations 品牌系列包括 Pure Encapsulations、Garden of Life、Wobenzym®、Genestra Brands、Douglas Laboratories 和 Klean Athlet
Reference
in Human Health and Disease, eds. Ronald Ross Watson, Victor R. Preedy, Sherma Zibadi (Academic Press: San Diego, 2013): 489–511.
“Our data indicate that GlucoPhenol may improve insulin sensitivity and prevent an increase in compensatory insulin secretion, representing a promising approach to improving glucose management in subjects at risk for type 2 diabetes,” explained Jacques. “These results are particularly encouraging, as they indicate that polyphenols may delay or even halt the progression to type 2 diabetes.”
The findings suggest that the cranberry and strawberry polyphenols found in GlucoPhenol may increase both insulin signaling and the transport of glucose into skeletal muscle, thus improving insulin sensitivity. Larger and longer-term studies will be needed, along with controlled dose-response trials to determine the lower and upper range of activity of these polyphenols.
“This latest research represents another significant advancement resulting from our collaboration with INAF,” explained Barry Ritz, Chief Scientific Officer for Atrium Innovations. “We have already incorporated the learnings from this study into Atrium Innovations products, and are committed to continued research to fuel innovation that will improve health outcomes for patients.”
While berries such as strawberries and cranberries are often referred to as “superfoods” and have numerous health benefits, the bioavailability of bioactive polyphenols in whole foods have been shown to be relatively poor.3,4 In the current study, however, the concentration of four active polyphenol compounds and metabolites from GlucoPhenol most likely responsible for the observed benefits were identified and measured in the blood of study participants. The GlucoPhenol used in the study consists of a proprietary blend of cranberry and Orléans strawberry extracts from North American farms and developed specifically by the study partners. This specific blend of polyphenols is now available exclusively in three products under Atrium Innovations’ Pure Encapsulations, Douglas Laboratories and Genestra brands.
This study is part of a multi-year research collaboration between INAF and Atrium Innovations, exploring the impact of lifestyle and nutritional interventions on cardiometabolic health. In addition to polyphenols, researchers have also explored clinical applications of fish oil and systemic enzymes and their role in improving cardiometabolic health outcomes.
STUDY METHODOLOGY:
The study included 41 healthy but insulin-resistant participants ranging in age from 40 to 70, each with a body mass index (BMI) ≥ 25 kg/m2, in a parallel, double-blind, controlled and randomized 6-week clinical trial. The consumption of berries, wine, polyphenol supplements and all products containing berries or wine was forbidden throughout the entire study period. Insulin sensitivity was assessed by the hyperinsulinemic-euglycemic clamp, and a 2-h oral glucose tolerance test was performed at the beginning and at the end of the experimental period. Results showed that GlucoPhenol increased insulin sensitivity (M/I) by 14% (+0·9 ± 0·5 x103 mg·kg-1·min-1·pmol-1) whereas control decreased insulin sensitivity (M/I) by 7% (-0·5 ± 0·5 x103 mg·kg-1·min-1·pmol-1), a 21% differential effect between groups. This improvement in insulin sensitivity was both statistically (P = 0·03) and clinically significant.
Atrium Innovations contributed the GlucoPhenol and control products used in this study. The study was supported by the Consortium de recherches et innovations en bioprocédés industriels du Québec (CRIBIQ), Atrium Innovations Inc., and Nutra Canada Inc. (now member of Diana Food Inc.)
For more information, view the full study here.
About the Institute of Nutrition and Functional Foods (INAF)
INAF is a recognized network of renowned multidisciplinary scientists working together to advance knowledge about human nutrition and its impact on health. Over the past ten years, INAF has put together the largest team of Canadian researchers (80+) dedicated to understanding the complex relationships between foods, food components, nutrition and health, and the role they play in prevention of chronic diseases. INAF puts science at the service of nutrition to fulfill its mission and ensure its actions lead to concrete and durable results that benefit the population’s health and the bio-food sector.
About Atrium Innovations
Atrium Innovations Inc. is a globally recognized leader in the development, manufacturing and commercialization of innovative, science-based, natural health products that are distributed in more than 35 countries. The company owns healthcare practitioner and specialized retail product brands that are at the forefront of science, innovation and education. Atrium has over 1,300 employees and operates seven manufacturing facilities, all of which comply with Current Good Manufacturing Practices. The family of Atrium Innovations brands includes Pure Encapsulations, Garden of Life, Wobenzym®, Genestra Brands, Douglas Laboratories and Klean Athlete.
1. International Diabetes Federation. https://www.idf.org/about-diabetes/facts-figures
2. American Diabetes Association. (December 2016) https://www.diabetes.org/diabetes-basics/statistics/
3. Cardona F, Andrés-Lacueva C, Tulipani S et al, “Benefits of Polyphenols on Gut Microbiota and Implications in Human Health,” J Nutr Biochem 24 (2013), 1415–1422.
4. Ziberna L, Fornazsaro S, Čvorović J et al, “Bioavailability of Flavonoids: The Role of Cell Membrane Transporters,” in Polyphenols
in Human Health and Disease, eds. Ronald Ross Watson, Victor R. Preedy, Sherma Zibadi (Academic Press: San Diego, 2013): 489–511.